CN107531674B - 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 - Google Patents

用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Download PDF

Info

Publication number
CN107531674B
CN107531674B CN201680018639.XA CN201680018639A CN107531674B CN 107531674 B CN107531674 B CN 107531674B CN 201680018639 A CN201680018639 A CN 201680018639A CN 107531674 B CN107531674 B CN 107531674B
Authority
CN
China
Prior art keywords
compound
pyrrolidine
pharmaceutically acceptable
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680018639.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107531674A (zh
Inventor
谢玲红
菲利普·格林·琼斯
凯瑞·L·斯皮尔
诺尔·阿伦·鲍威尔
泰琳·G·阿纳尼亚
瓦迪姆·亚历山德罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pgi Drug Development Corp
Sumitomo Pharma America Inc
Original Assignee
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Development Corp, Sunovion Pharmaceuticals Inc filed Critical Pgi Drug Development Corp
Priority to CN202010607608.6A priority Critical patent/CN111925360B/zh
Publication of CN107531674A publication Critical patent/CN107531674A/zh
Application granted granted Critical
Publication of CN107531674B publication Critical patent/CN107531674B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680018639.XA 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Expired - Fee Related CN107531674B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
US62/115,064 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010607608.6A Division CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Publications (2)

Publication Number Publication Date
CN107531674A CN107531674A (zh) 2018-01-02
CN107531674B true CN107531674B (zh) 2020-07-31

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680018639.XA Expired - Fee Related CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN202010607608.6A Expired - Fee Related CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010607608.6A Expired - Fee Related CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Country Status (22)

Country Link
US (4) US9856238B2 (https=)
EP (2) EP4046995B1 (https=)
JP (3) JP6657241B2 (https=)
KR (1) KR102601972B1 (https=)
CN (2) CN107531674B (https=)
AU (1) AU2016219253C1 (https=)
CA (1) CA2976095C (https=)
CY (1) CY1125198T1 (https=)
DK (1) DK3256466T3 (https=)
EA (1) EA201791804A1 (https=)
ES (2) ES2967643T3 (https=)
HU (1) HUE058698T2 (https=)
IL (1) IL253914B (https=)
MX (2) MX371404B (https=)
MY (1) MY188160A (https=)
NZ (1) NZ735011A (https=)
PH (1) PH12017501422A1 (https=)
PL (1) PL3256466T3 (https=)
PT (1) PT3256466T (https=)
SG (2) SG11201706515QA (https=)
UA (1) UA122222C2 (https=)
WO (1) WO2016130796A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623321B1 (ko) * 2015-02-11 2024-01-09 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
KR102601972B1 (ko) * 2015-02-11 2023-11-13 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
CA3104811C (en) 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393759A (en) * 1990-05-25 1995-02-28 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
ATE252572T1 (de) 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
RU2004117211A (ru) * 2001-11-08 2005-03-27 Сепракор, Инк. (Us) Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама
CA2591810A1 (en) * 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
WO2006116165A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CA2637261A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
KR102601972B1 (ko) * 2015-02-11 2023-11-13 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393759A (en) * 1990-05-25 1995-02-28 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Asymmetric routes towards polyfunctionalized pyrrolidines:application to the synthesis of alkaloid analogues;Martial Toffano, et al.;《Tetrahedron: Asymmetry》;20131231;3365-3370 *

Also Published As

Publication number Publication date
AU2016219253C1 (en) 2022-12-08
SG10201806809QA (en) 2018-09-27
US20220185799A1 (en) 2022-06-16
JP2022065050A (ja) 2022-04-26
EP4046995C0 (en) 2023-09-13
AU2016219253B2 (en) 2020-10-01
JP2020079282A (ja) 2020-05-28
CN107531674A (zh) 2018-01-02
US20190389845A1 (en) 2019-12-26
IL253914B (en) 2021-09-30
PH12017501422A1 (en) 2018-03-19
JP2018505205A (ja) 2018-02-22
KR20170129730A (ko) 2017-11-27
CA2976095C (en) 2023-10-17
AU2016219253A1 (en) 2017-09-21
BR112017017354A2 (pt) 2018-04-10
IL253914A0 (en) 2017-10-31
MX2017010363A (es) 2018-05-04
DK3256466T3 (da) 2022-05-02
CN111925360B (zh) 2024-03-22
ES2911910T3 (es) 2022-05-23
SG11201706515QA (en) 2017-09-28
US11192885B2 (en) 2021-12-07
EP3256466B9 (en) 2022-07-27
CA2976095A1 (en) 2016-08-18
NZ735011A (en) 2023-07-28
WO2016130796A1 (en) 2016-08-18
MX392664B (es) 2025-03-24
US10336732B2 (en) 2019-07-02
EP4046995B1 (en) 2023-09-13
ES2911910T9 (es) 2022-08-12
MX2020001157A (es) 2022-05-27
US20180093974A1 (en) 2018-04-05
KR102601972B1 (ko) 2023-11-13
PL3256466T3 (pl) 2022-05-23
US20170001987A1 (en) 2017-01-05
MY188160A (en) 2021-11-24
CY1125198T1 (el) 2024-12-13
HUE058698T2 (hu) 2022-09-28
EP3256466B1 (en) 2022-04-06
ES2967643T3 (es) 2024-05-03
PT3256466T (pt) 2022-05-10
EP4046995A1 (en) 2022-08-24
CN111925360A (zh) 2020-11-13
JP6657241B2 (ja) 2020-03-04
UA122222C2 (uk) 2020-10-12
EA201791804A1 (ru) 2018-02-28
EP3256466A1 (en) 2017-12-20
JP7023994B2 (ja) 2022-02-22
US9856238B2 (en) 2018-01-02
MX371404B (es) 2020-01-29

Similar Documents

Publication Publication Date Title
CN107531674B (zh) 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN107567454B (zh) 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物
TWI813673B (zh) 抗增生化合物及其用途
CN111183138A (zh) 异色满化合物以及用途
HK40042391A (en) 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
BR112017017354B1 (pt) Composto e seu uso, composição, processo para preparar um composto
HK1241876B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA046724B1 (ru) Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200731

CF01 Termination of patent right due to non-payment of annual fee